Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 755

1.

Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.

Miura S, Nakashima M, Ito M, Kondo H, Meirmanov S, Hayashi T, Soda M, Matsuo T, Sekine I.

Cancer. 2008 May 15;112(10):2143-51. doi: 10.1002/cncr.23414.

2.

Significance of genomic instability in breast cancer in atomic bomb survivors: analysis of microarray-comparative genomic hybridization.

Oikawa M, Yoshiura K, Kondo H, Miura S, Nagayasu T, Nakashima M.

Radiat Oncol. 2011 Dec 7;6:168. doi: 10.1186/1748-717X-6-168.

3.

Prognostic relevance of gene amplifications and coamplifications in breast cancer.

Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Köchli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G.

Cancer Res. 2004 Dec 1;64(23):8534-40.

4.

Genomic instability in the epidermis induced by atomic bomb (A-bomb) radiation: a long-lasting health effect in A-bomb survivors.

Naruke Y, Nakashima M, Suzuki K, Kondo H, Hayashi T, Soda M, Sekine I.

Cancer. 2009 Aug 15;115(16):3782-90. doi: 10.1002/cncr.24405.

6.

Predominance of high-grade pathway in breast cancer development of Middle East women.

Al-Kuraya K, Schraml P, Sheikh S, Amr S, Torhorst J, Tapia C, Novotny H, Spichtin H, Maurer R, Mirlacher M, Simon R, Sauter G.

Mod Pathol. 2005 Jul;18(7):891-7.

7.

Risk factors for primary breast cancer in Japan: 8-year follow-up of atomic bomb survivors.

Goodman MT, Cologne JB, Moriwaki H, Vaeth M, Mabuchi K.

Prev Med. 1997 Jan-Feb;26(1):144-53.

PMID:
9010910
8.

Incidence of multiple primary cancers in Nagasaki atomic bomb survivors: association with radiation exposure.

Nakashima M, Kondo H, Miura S, Soda M, Hayashi T, Matsuo T, Yamashita S, Sekine I.

Cancer Sci. 2008 Jan;99(1):87-92. Epub 2007 Nov 2.

9.

Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.

Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.

Oncol Rep. 2008 Mar;19(3):651-6.

PMID:
18288397
10.

Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array.

Rummukainen JK, Salminen T, Lundin J, Kytölä S, Joensuu H, Isola JJ.

Mod Pathol. 2001 Oct;14(10):1030-5.

11.

Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.

Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H, Klijn JG.

Gene. 1995 Jun 14;159(1):11-8.

PMID:
7607564
12.

Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.

Shimada M, Imura J, Kozaki T, Fujimori T, Asakawa S, Shimizu N, Kawaguchi R.

Oncol Rep. 2005 Apr;13(4):633-41.

PMID:
15756435
13.

Male breast cancer incidence among atomic bomb survivors.

Ron E, Ikeda T, Preston DL, Tokuoka S.

J Natl Cancer Inst. 2005 Apr 20;97(8):603-5.

14.

Are cancer risks associated with exposures to ionising radiation from internal emitters greater than those in the Japanese A-bomb survivors?

Little MP, Hall P, Charles MW.

Radiat Environ Biophys. 2007 Nov;46(4):299-310. Epub 2007 Jul 17.

PMID:
17639450
16.

Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes.

Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ.

Mod Pathol. 2010 Jul;23(7):1029-39. doi: 10.1038/modpathol.2010.84. Epub 2010 May 14.

17.

Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis.

Ottestad L, Andersen TI, Nesland JM, Skrede M, Tveit KM, Nustad K, Børresen AL.

Acta Oncol. 1993;32(3):289-94.

PMID:
8100712
18.

Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.

Gaffey MJ, Frierson HF Jr, Williams ME.

Mod Pathol. 1993 Nov;6(6):654-9.

PMID:
7905628
19.

c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.

Wang ZR, Liu W, Smith ST, Parrish RS, Young SR.

Exp Mol Pathol. 1999 Jun;66(2):140-8.

PMID:
10409442
20.

Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification.

Berns EM, Foekens JA, van Putten WL, van Staveren IL, Portengen H, de Koning WC, Klijn JG.

J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):13-9.

PMID:
1356012
Items per page

Supplemental Content

Write to the Help Desk